Last reviewed · How we verify
GSK2269557 — Competitive Intelligence Brief
phase 2
HDAC6 inhibitor
HDAC6
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK2269557 (GSK2269557) — GlaxoSmithKline. GSK2269557 is a selective inhibitor of the histone deacetylase 6 (HDAC6).
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK2269557 TARGET | GSK2269557 | GlaxoSmithKline | phase 2 | HDAC6 inhibitor | HDAC6 | |
| Vorinostat (VOR) | Vorinostat (VOR) | University of North Carolina, Chapel Hill | marketed | Histone deacetylase (HDAC) inhibitor | Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (HDAC6 inhibitor class)
- CrystalGenomics, Inc. · 1 drug in this class
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK2269557 CI watch — RSS
- GSK2269557 CI watch — Atom
- GSK2269557 CI watch — JSON
- GSK2269557 alone — RSS
- Whole HDAC6 inhibitor class — RSS
Cite this brief
Drug Landscape (2026). GSK2269557 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2269557. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing